Cooper J, Raeburn A L, Brumfitt W, Hamilton-Miller J M
Earnswood Medical Centre, Crewe, London, UK.
Chemotherapy. 1990;36 Suppl 1:24-6. doi: 10.1159/000238811.
A clinical trial comparing 5 days' treatment with amoxycillin/clavulanate (group A) and a single dose of fosfomycin trometamol (group B) is presented. The study was done in symptomatic patients presenting to their family practitioner, with the microbiological testing being carried out in a university hospital laboratory. Of 62 patients with significant bacteriuria, 29 were given amoxycillin/clavulanate and 33 fosfomycin trometamol, in a randomized fashion. Cure rates 1 week and 5 weeks after the end of treatment were 72 and 65% in group A and 85 and 81% in group B. Adverse events assessed in 141 patients were unusual (10.1% in group A and 8.3% in group B) and were mild in nature. The results of this study suggest that single-dose treatment with fosfomycin trometamol is effective and acceptable as a conventional course of amoxycillin clavulanate for the treatment of simple acute dysuria and/or frequency with infection.
本文介绍了一项临床试验,该试验比较了阿莫西林/克拉维酸治疗5天(A组)和单剂量磷霉素氨丁三醇(B组)的疗效。该研究针对出现症状后前往家庭医生处就诊的患者开展,微生物检测在大学医院实验室进行。62例有明显菌尿的患者被随机分为两组,29例接受阿莫西林/克拉维酸治疗,33例接受磷霉素氨丁三醇治疗。治疗结束后1周和5周时,A组的治愈率分别为72%和65%,B组分别为85%和81%。在141例患者中评估的不良事件不常见(A组为10.1%,B组为8.3%),且性质轻微。本研究结果表明,对于单纯急性排尿困难和/或伴有感染的尿频,单剂量磷霉素氨丁三醇治疗与常规疗程的阿莫西林克拉维酸治疗一样有效且可接受。